Note 8 - Intangible Assets, net:

($ amounts in thousands)


	June 30,		December 31,
	2011		2010
QOL Medical, LLC Asset Purchase Agreement, net of accumulated amortization of $10,260 and $7,980	$	44,461	$	46,741
BioAlliance Licensing Agreement, net of accumulated amortization of $1,399 and $559		-		19,441
Glenmark Generics Limited and Glenmark Generics, Inc. USA Licensing Agreement, net of accumulated amortization of $0		15,000		15,000
MonoSol Rx Licensing Agreement, net of accumulated amortization of $350 and $125		-		5,875
Trademark licensed from Bristol-Myers Squibb Company, net of accumulated amortization of $8,183 and $7,433		1,817		2,567
Genpharm, Inc. Distribution Agreement, net of accumulated amortization of $9,387 and $9,026		1,446		1,807
SVC Pharma LP License and Distribution Agreement, net of accumulated amortization of $2,723 and $2,525		961		1,159
MDRNA, Inc. Asset Purchase Agreement, net of accumulated amortization of $1,294 and $770		806		1,330
Spectrum Development and Marketing Agreement, net of accumulated amortization of $24,805 and $24,254		195		746
Other intangible assets, net of accumulated amortization of $6,336 and $5,947		887		801
	$	65,573	$	95,467

We recorded amortization expense related to intangible assets of $6,118 thousand for the six months ended June 30, 2011 and $8,154 thousand for the six months ended June 30, 2010. The majority of this amortization expense was included in cost of goods sold. We also recorded $24,226 thousand of intangible asset impairment charges in the three months and six months ended June 30, 2011. The impairment charges were included in "Restructuring costs" on the condensed consolidated statements of operations for the three months and six months ended June 30, 2011. Refer to Note 18 – "Restructuring Costs" for further details.

In July 2010, the FDA approved Zuplenz®, an oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting. In June 2008, Strativa and MonoSol Rx entered into an exclusive licensing agreement under which Strativa acquired the U.S. commercialization rights to Zuplenz®. Under the terms of an amended agreement, the FDA approval triggered Strativa's payments to MonoSol Rx of a $4,000 thousand approval milestone and a $2,000 thousand pre-launch milestone. Strativa began to commercialize Zuplenz®, which was supplied by MonoSol, during the fourth quarter of 2010. Amortization expense of the related intangible asset commenced when the product was launched in the fourth quarter of 2010. In June 2011, we stopped marketing Zuplenz® as part of plans to resize Strativa. We also reduced our Strativa workforce by a total of approximately 90 people and we recorded intangible asset impairment charges as part of this strategic assessment. In July 2011, Strativa returned the U.S. commercialization rights of Zuplenz® to MonoSol, as part of the resizing of our branded products division. Refer to Note 18 – "Restructuring Costs" for further details.

In May 2010, Par entered into a licensing agreement with Glenmark Generics to market ezetimibe 10 mg tablets, the generic version of Merck & Co. Inc.'s Zetia®, in the U.S. Glenmark believes it is the first to file an ANDA containing a paragraph IV certification for the product, which would potentially provide 180 days of marketing exclusivity. On April 24, 2009, Glenmark was granted tentative approval for its product by the FDA. Under the terms of the licensing and supply agreement, we made a $15,000 thousand payment to Glenmark for exclusive rights to market, sell and distribute the product in the U.S. The companies will participate in a profit sharing arrangement based on any future sales of the product. Glenmark will supply the product subject to FDA approval. The product has a contractual launch date of no later than December 2016. Under defined conditions, the product could be launched earlier than December 2016. Amortization expense of the related intangible asset will commence when the product is launched.

In April 2010, the FDA approved OravigTM, an antifungal therapy for the treatment of oropharyngeal candidiasis, an opportunistic infection commonly found in immunocompromised patients, including those with HIV and cancer. Under the terms of Strativa's exclusive U.S. license agreement with BioAlliance, we paid BioAlliance $20,000 thousand in the second quarter of 2010 as a result of the FDA approval. Strativa began to commercialize OravigTM, which was supplied by BioAlliance, during the third quarter of 2010. In June 2011, we decided to reduce our marketing efforts for this product as part of plans to resize Strativa. We also reduced our Strativa workforce by a total of approximately 90 people and we recorded intangible asset impairment charges as part of this strategic assessment. Refer to Note 18 – "Restructuring Costs" for further details.

In March 2009, we acquired the rights to Nascobal® Nasal Spray from QOL Medical, LLC for $54,500 thousand in cash and the assumption of certain liabilities. The purchase price of the acquisition has been allocated to the net tangible and intangible assets acquired on the basis of estimated fair values. The fair value of the product rights received is being amortized on a straight-line basis over 12 years based on its estimated useful life.

Estimated Amortization Expense for Existing Intangible Assets at June 30, 2011

The following table does not include estimated amortization expense for future milestone payments that may be paid and result in the creation of intangible assets after June 30, 2011.

($ amounts in thousands)


	Estimated
	Amortization
	Expense
2011 (remainder)	$	4,544
2012		7,122
2013		5,447
2014		4,680
2015		4,605
2016 and thereafter		39,175
	$	65,573

As of June 30, 2011, we did not note any business circumstances or events that would indicate any of our remaining net intangible assets were impaired.